Personalized medicine in cytokine-targeted therapy;Personalisierte Medizin bei Zytokin-gerichteten Therapien

Zeitschrift fur Rheumatologie

Volumn 72, Issue 1, 2013, Pages 41-48

  Behrens, F ^a   Kohm M ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Cytokine; Personalized healthcare; Safety profile; Stratification; Therapy

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ALLOPATHY; ARTICLE; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GENETIC MARKER; HUMAN; MOLECULARLY TARGETED THERAPY; PERSONALIZED MEDICINE; RHEUMATIC DISEASE;

EID: 84873692597     PISSN: 03401855     EISSN: 14351250     Source Type: Journal    
DOI: 10.1007/s00393-011-0886-3     Document Type: Article

References (33)

1. Adkins DE, Aberg K, McClay JL, et al (2011) Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol Psychiatry 16(3):321-332
2. Allantaz F, Chaussabel D, Stichweh D, et al (2007) Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med 204(9):2131-2144
3. Ambarus C, Yeremenko N, Tak PP, et al (2012) Pathogenesis of spondyloarthritis: autoimmune or autoinflammatory? Curr Opin Rheumatol 24(4):351-358
4. Anlauf M (2012) Symposium der Arzneimittelkommission der deutschen Ärzteschaft. 4. Febr. 2012, Berlin
5. Benucci M, Saviola G, Baiardi P, et al (2012) Determinants of risk infection during therapy with anti TNF-alpha blocking agents in rheumatoid arthritis. Open Rheumatol J 6:33-37
6. Cheadle WG, Hershman MJ, Wellhausen SR, et al (1991) HLA-DR antigen expression on peripheral blood monocytes correlates with surgical infection. Am J Surg 161(6):639-645
7. Choy E (2012) Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 51(Suppl 5):v3-v11
8. Cohen SB, Emery P, Greenwald MW, et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54(9):2793-2806
9. Cope AP, et al (1992) Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 35:1160-1169
10. Cui J, Saevarsdottir S, Thomson B, et al (2010) Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum 62(7):1849-1861
11. Duvallet E, Semerano L, Assier E, et al (2011) Interleukin-23: a key cytokine in inflammatory diseases. Ann Med 43(7):503-511
12. Fishman D, Faulds G, Jeffery R, et al (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102(7):1369-1376
13. Fox DA (2012) Kinase inhibition - a new approach to the treatment of rheumatoid arthritis. N Engl J Med 367(6):565-567
14. Genovese MC, Becker JC, Schiff M, et al (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353(11):1114-1123
15. Grijalva CG, Chen L, Delzell E, et al (2011) Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 306(21):2331-2339
16. Gonzales-Alvaro I, Ortiz AM, Alvaro-Gracia JM, et al (2011) Interleukin 15 levels in serum may predict a severe disease course in patients with early arthritis. PLoS One 6(12):e29492
17. Kayakabe K, Kuroiwa T, Sakurai N, et al (2012) Interleukin-1β measurement in stimulated whole blood cultures is useful to predict response to anti-TNF therapies in rheumatoid arthritis. Rheumatology (Oxford) 51(9):1639-1643
18. Kirkham BW, Lassere MN, Edmonds JP, et al (2006) Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 54(4):1122-1131
19. Klaasen R, Cantaert T, Wijbrandts CA, et al (2011) The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study. Rheumatology (Oxford) 50(8):1487-1493
20. Klaasen R, Thurlings RM, Wijbrandts CA, et al (2009) The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study. Arthritis Rheum 60(11):3217-3224
21. Littman BH (2009) Tocilizumab and missed personalized medicine opportunities for patients with rheumatoid arthritis? Arthritis Rheum 60(5):1565-1566
22. Nardini C, Annoni M, Schiavone G (2012) Mechanistic understanding in clinical practice: complementing evidence-based medicine with personalized medicine. J Eval Clin Pract 18(5):1000-1005
23. Stiftung PM. Homepage: http://www.pmstiftung.eu
24. Putte LB van de, Atkins C, Malaise M, et al (2004) Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63(5):508-516
25. Simard JF, Neovius M, Askling J for the ARTIS Study Group (2012) Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish biologics register. Arthritis Rheum 64(11):3502-3510
26. Smolen JS, Beaulieu A, Rubbert-Roth A, et al (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371(9617):987-997
27. Strangfeld A, Listing J, Herzer P, et al (2009) Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301(7):737-744
28. Su DL, Lu ZM, Shen MN, et al (2012) Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE. J Biomed Biotechnol 2012:347141
29. Tak PP (2012) A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm. Rheumatology (Oxford) 51(4):600-609
30. Ulfgren AK, Andersson U, Engström M, et al (2000) Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 43(11):2391-2396
31. Wijbrandts CA, Dijkgraaf MG, Kraan MC, et al (2008) The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann Rheum Dis 67(8):1139-1144
32. Zhou ZY, Chen SL, Shen N, Lu Y (2012) Cytokines and Behcets disease. Autoimmun Rev 11(10):699-704
33. Zong M, Loell I, Lindroos E, et al (2012) Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor α expression in muscle tissues of patients with polymyositis or dermatomyositis. Ann Rheum Dis 71(6):1055-1063